Fighting back feelings of fatigue, irritability, or depression?Before you diagnose yourself with a chronic condition, take a look at your diet. Sometimes, common medical symptoms can signal a nutritional deficiency. In the United States, 1 in 10 people have at least one nutritional deficiency, says Christine Pfeiffer, PhD, a research chemist…

The teen said she wanted to lose weight.

Dear Editors:I am rather stunned that the BMJ published a journalist’s commentary about the work of the 2015 United States Dietary Guidelines Advisory Committee as if it were an authoritative rebuttal. It’s as if someone selling horse paperweights is invited to critique the Olympic equestrian team. It is, in a word, absurd- and testimony to the…

(This story has been refiled to correct the affiliation of researcher in paragraph 3) By Kathryn Doyle (Reuters Health) – In a head-to-head comparison over 15 years, diet and exercise outperformed the drug metformin in preventing people at high risk for diabetes from developing the disease. Metformin, which helps control blood sugar and can be used alone or in combination with insulin to treat type 2 diabetes, also lowered the risk of developing the disorder in the study group, just not as much as making healthy lifestyle changes did. “The lifestyle intervention was more powerful in preventing or delaying diabetes development during the original three-year Diabetes Prevention Program and remains more powerful over the entire 15-year study,” said professor David M. Nathan of the Massachusetts General Hospital in Boston, a coauthor of the new paper.

An enhanced inflammatory response could be the key link between high saturated fat intake – a recognized risk factor for obesity-related disorders – and the development of diseases like type 2…

COPENHAGEN (Reuters) – Danish pharmaceutical company Novo Nordisk has successfully completed the second phase 3a trial with its diabetes drug semaglutide, it said on Friday. “We are excited about these trial results, which show that 1.0 mg semaglutide injected once weekly provided better glycaemic control and greater weight loss than 2.0 mg exenatideonce-weekly,” chief science officer Mads Krogsgaard Thomsen said in a statement. Novo Nordisk said semaglutide appeared to have a safe and well-tolerated profile. (Reporting by Teis Jensen; editing by David Clarke)